

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREEN FRESH BIOTECHNOLOGY COMPANY LIMITED

綠新生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code:1084)

UPDATE ON FINANCIAL INFORMATION

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Green Fresh Biotechnology Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).

Following a preliminary review of the currently available information which includes, but without limitation to, the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the “**Reporting Period**”), the Board wishes to inform the shareholders (the “**Shareholders**”) and the prospective investors of the Company that the Company is expected to record a net loss attributable to owners of the Company in the range of approximately RMB1.0 million to RMB4.0 million for the Reporting Period, as compared to the net loss attributable to owners of the Company of RMB12.07 million for the six months ended 30 June 2025.

Such improvement in the performance of the Group was primarily due to the increase in the sales volume of carrageenan products as a result of the Group’s competitive pricing strategy, which contributed to the growth in both revenue and gross profit for the Reporting Period.

The aforementioned improvement in sales revenue has also contributed to the improvement in the Group’s net operating cash inflow for the Reporting Period by over 7 times as compared with that for the six months ended 30 June 2025.

The Company is in the process of finalising the unaudited consolidated interim results of the Group for the Reporting Period. Hence, the information disclosed in this announcement only represents a preliminary assessment by the Board based on the information currently available to the Board. The interim results of the Group for the Reporting Period are subject to adjustments following the review by the Board and the auditors of the Company. The Board expects that the announcement of the interim results of the Group for the Reporting Period will be published before the end of August 2026 in full compliance with the requirements under the Listing Rules.

Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Green Fresh Biotechnology Company Limited
CHAN Kam Chung
Chairman and Chief Executive Officer

Hong Kong, 12 August 2026

As of the date of this announcement, the executive Directors are Mr. CHAN Kam Chung (Chairman and Chief Executive Officer), Mr. GUO Dongxu, Mr. CHAN Shui Yip, Mr. SHE Xiaoying and Ms. CHEN Yi; and the independent non-executive Directors are Mr. HO Kwai Ching, Mark, Mr. NG Man Kung and Mr. HU Guohua.